Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 223.0% in July
Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 223.0% in July
(Get Rating)Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 612,400 shares, a growth of 223.0% from the June 30th total of 189,600 shares. Based on an average daily trading volume, of 706,600 shares, the days-to-cover ratio is presently 0.9 days.
埃斯隆醫療公司(納斯達克：AEMD-GET評級)是7月份空頭股數業務大幅增長的接受者。截至7月15日，空頭股數共有612,400股，較6月30日的189,600股增長223.0%。以日均成交量706,600股計算，目前天數與回補比率為0.9天。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, StockNews.com began coverage on shares of Aethlon Medical in a research note on Saturday, July 16th. They set a "sell" rating on the stock.
另外，StockNews.com在7月16日星期六的一份研究報告中開始報道Aethlon Medical的股票。他們對該股設定了“賣出”評級。
Institutional Trading of Aethlon Medical
愛思強醫療的制度性交易
An institutional investor recently bought a new position in Aethlon Medical stock. NTB Financial Corp acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 17,425 shares of the medical equipment provider's stock, valued at approximately $32,000. NTB Financial Corp owned 0.11% of Aethlon Medical at the end of the most recent reporting period. Institutional investors own 10.58% of the company's stock.
一家機構投資者最近買入了Aethlon Medical股票的新頭寸。根據NTB金融公司最近向美國證券交易委員會提交的13F文件，該公司在第四季度收購了埃斯隆醫療公司(納斯達克代碼：AEMD-GET Rating)的新股份。該機構投資者購買了這家醫療設備供應商的17,425股股票，價值約32,000美元。在最近的報告期結束時，NTB金融公司擁有Aethlon Medical 0.11%的股份。機構投資者持有該公司10.58%的股票。
Aethlon Medical Price Performance
艾司朗醫療價格表現
Aethlon Medical Company Profile
艾斯隆醫療公司簡介
(Get Rating)
(獲取評級)
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.
Aethlon Medical，Inc.是一家醫療技術公司，專注於開發在美國診斷和治療危及生命和器官的疾病的產品。該公司開發艾司朗血液淨化器，這是一種臨牀階段的免疫治療設備，可以從人類循環系統中移除腫瘤衍生的外小體和威脅生命的病毒，包括移除新冠肺炎病毒、相關變異體和相關的外小體。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Aethlon Medical (AEMD)
- Shopify Stock Rallies Despite Quarterly Loss
- Two Automation Stocks The Institutions Are Buying
- Can Owens-Corning Insulate Your Portfolio?
- Consumer Staple Kraft-Heinz Quietly Builds Momentum
- Steady, Stable Kimberly-Clark Yields 3.4%
- 免費獲取StockNews.com關於Aethlon Medical(AEMD)的研究報告
- 儘管季度虧損，但Shopify股市反彈
- 兩家機構正在購買的兩隻自動化股票
- 歐文斯-康寧能隔離你的投資組合嗎？
- 消費品卡夫-亨氏悄然形成勢頭
- 穩定，穩定的金佰利收益率為3.4%
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《艾斯龍醫學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aethlon Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。
